Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such
OwnerRobert Jordan, Diane D. Petrone +1inventors
InventorsRobert Jordan, Diane D. Petrone, Mary Ryan
Life of this patent
Estimating the term…
Abstract
The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG breakdown products retaining antigen binding but having lost effector functions.
Claims28
An antibody composition that comprises at least one antibody that specifically binds to an IgG protease cleavage product characterized by, a) having molecular weight which is comparable to an intact mammalian IgG under non-denaturing conditions and b) being separable into two fragments which comprise an antigen binding fragment of 135 kDa and a CH2-containing fragment under denaturing but non-reducing conditions and c) wherein the reagent does not react with intact IgG.
An human IgG protease cleavage site peptide analog consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:
- 5-11.
A method of detecting a disease process in a subject by analysis of a tissue sample from the subject, wherein said method comprises the detection of a proteolytically cleaved IgG characterized by a) having a molecular weight which is comparable to an intact mammalian IgG under physiological conditions and b) being separable into two fragments which comprise an antigen binding fragment of 135 kDa and a 25 kDa fragment under denaturing but non-reducing conditions.
A kit including a reagent for detection of a disease marker in tissue of a subject, which reagent comprises at least one antibody that specifically binds to a cleaved IgG, which antibody is capable of detecting an IgG cleavage product characterized by a) having molecular weight which is comparable to an intact mammalian IgG under non-denaturing conditions and b) being separable into two fragments which comprise an antigen binding fragment of 135 kDa and a CH2-containing fragment under denaturing but non-reducing conditions and c) wherein the reagent does not react with intact IgG.
Dependencies are inferred from the claim text.